干扰素在慢性淋巴细胞白血病中的作用

Emilio Montserrat , Neus Villamor , Alvaro Urbano-Ispizua , Josep-Maria Ribera , Ciril Rozman
{"title":"干扰素在慢性淋巴细胞白血病中的作用","authors":"Emilio Montserrat ,&nbsp;Neus Villamor ,&nbsp;Alvaro Urbano-Ispizua ,&nbsp;Josep-Maria Ribera ,&nbsp;Ciril Rozman","doi":"10.1016/0277-5379(91)90580-7","DOIUrl":null,"url":null,"abstract":"<div><p>The role of alpha interferon in patients with chronic lymphocytic leukaemia (CLL) has yet to be well established. In studies carried out to date, a significantly higher response rate has been observed in previously untreated patients compared to those who have received prior chemotherapy. Patients with early-stage CLL also respond better than patients with advanced disease. Responses to alpha interferon are transient and complete responses are rare. It is not yet known whether alpha interferon can induce clonal remission, and response is usually measured in terms of the reduction in peripheral blood lymphocyte levels. In one study, a normalization of immunoglobulin levels was observed, and in another there was an increase in the absolute number of granulocytes. Further studies are needed to investigate the role of combined therapy with alpha interferon and cytotoxic agents or other cytokines, and to assess the ability of alpha interferon to prolong response duration after remission induction with chemotherapy. Toxicity is tolerable when alpha interferon is given in a low dose (e.g., 2 million units (MU)/m<sup>2</sup> three times a week) and low doses have been shown to be as effective as high doses in CLL patients.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90580-7","citationCount":"16","resultStr":"{\"title\":\"Alpha interferon in chronic lymphocytic leukaemia\",\"authors\":\"Emilio Montserrat ,&nbsp;Neus Villamor ,&nbsp;Alvaro Urbano-Ispizua ,&nbsp;Josep-Maria Ribera ,&nbsp;Ciril Rozman\",\"doi\":\"10.1016/0277-5379(91)90580-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The role of alpha interferon in patients with chronic lymphocytic leukaemia (CLL) has yet to be well established. In studies carried out to date, a significantly higher response rate has been observed in previously untreated patients compared to those who have received prior chemotherapy. Patients with early-stage CLL also respond better than patients with advanced disease. Responses to alpha interferon are transient and complete responses are rare. It is not yet known whether alpha interferon can induce clonal remission, and response is usually measured in terms of the reduction in peripheral blood lymphocyte levels. In one study, a normalization of immunoglobulin levels was observed, and in another there was an increase in the absolute number of granulocytes. Further studies are needed to investigate the role of combined therapy with alpha interferon and cytotoxic agents or other cytokines, and to assess the ability of alpha interferon to prolong response duration after remission induction with chemotherapy. Toxicity is tolerable when alpha interferon is given in a low dose (e.g., 2 million units (MU)/m<sup>2</sup> three times a week) and low doses have been shown to be as effective as high doses in CLL patients.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90580-7\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0277537991905807\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0277537991905807","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16

摘要

α干扰素在慢性淋巴细胞白血病(CLL)患者中的作用尚未得到很好的证实。在迄今为止进行的研究中,与先前接受过化疗的患者相比,先前未接受治疗的患者的反应率明显更高。早期CLL患者的反应也比晚期患者好。对干扰素的反应是短暂的,完全的反应是罕见的。目前尚不清楚α干扰素是否能诱导克隆缓解,反应通常是根据外周血淋巴细胞水平的降低来衡量的。在一项研究中,观察到免疫球蛋白水平正常化,而在另一项研究中,粒细胞的绝对数量增加。需要进一步研究α干扰素与细胞毒性药物或其他细胞因子联合治疗的作用,并评估α干扰素在化疗诱导缓解后延长反应持续时间的能力。当α干扰素以低剂量(例如,每周三次,200万单位(MU)/m2)给予时,毒性是可以容忍的,并且在CLL患者中,低剂量已被证明与高剂量一样有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Alpha interferon in chronic lymphocytic leukaemia

The role of alpha interferon in patients with chronic lymphocytic leukaemia (CLL) has yet to be well established. In studies carried out to date, a significantly higher response rate has been observed in previously untreated patients compared to those who have received prior chemotherapy. Patients with early-stage CLL also respond better than patients with advanced disease. Responses to alpha interferon are transient and complete responses are rare. It is not yet known whether alpha interferon can induce clonal remission, and response is usually measured in terms of the reduction in peripheral blood lymphocyte levels. In one study, a normalization of immunoglobulin levels was observed, and in another there was an increase in the absolute number of granulocytes. Further studies are needed to investigate the role of combined therapy with alpha interferon and cytotoxic agents or other cytokines, and to assess the ability of alpha interferon to prolong response duration after remission induction with chemotherapy. Toxicity is tolerable when alpha interferon is given in a low dose (e.g., 2 million units (MU)/m2 three times a week) and low doses have been shown to be as effective as high doses in CLL patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信